Aripiprazole: 8 agencies, 2004–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
On the same population the two systems disagree outright: AWMSG (Wales) recorded recommended for “Treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in ce…”, while SMC (Scotland) recorded not recommended for “for the treatment of moderate to severe manic episodes in bipolar I disorder and for the prevention of a new manic episode in patients who experienced predominantly manic…”.
The file has been open for more than a decade: 21.1 years separate the first record, 11 Jun 2004 at TLV (Sweden), from the most recent, 2025 at PBAC (Australia).
AWMSG (Wales) changed its position: not recommended on 10 Feb 2009, recommended by 14 Aug 2014, after a resubmission.
No assessment is on file from G-BA (Germany), which is among the eight highest-volume agencies here.
The file is active: 8 of 41 records date from 2023 or later.
The programme is broad: 8 distinct indication wordings are recorded for aripiprazole by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
5 of these 41 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
TLV (Sweden) was first to assess aripiprazole, on 11 Jun 2004; CIPM (Spain) did not open a file until 23 Nov 2023 — an unusually long tail of 19.4 years between the earliest and latest system to look at it.
The record arrives in waves: 8 separate years each carry two or more decisions, spread across 18 years in total.
8 of the 8 agencies here assessed aripiprazole more than once, HAS (France) most often at 12 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for aripiprazole.
The full ledger for aripiprazole reads 24 recommended, 8 other, 3 not recommended and 2 not assessed, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2025 | Schizophrenia | Recommended | source |
| TLV (Sweden) | 11 Jul 2024 | Abilify Maintena 960 mg ingår i högkostnadsskyddet | general subsidy | source |
| CIPM (Spain) | 23 Nov 2023 | Indicacio nes terapéutica s autorizada s: - Tratamiento de la esquizofrenia en adultos y adolescentes de 15 años o más. … | not financed by the SNS · art. 92 d | source |
| AWMSG (Wales) | 19 Mar 2015 | Maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole | outside AWMSG criteria | source |
| HAS (France) | 23 Apr 2014 | Listing (Transparency Committee) | ASMR V | source |
36 further decisions for aripiprazole, across 8 agencies, are not shown here. They link to 25 further source documents.
Related molecules
- risperidone — same ATC class N05A — Psycholeptics
- paliperidone — same ATC class N05A — Psycholeptics
- olanzapine — same ATC class N05A — Psycholeptics
- quetiapine — same ATC class N05A — Psycholeptics
- lurasidone — same ATC class N05A — Psycholeptics
- droperidol — same ATC class N05A — Psycholeptics
Coverage: 41 decisions for aripiprazole from 8 agencies, 2004 to 2025. Data to 7 Sep 2026. ATC class N05A — Psycholeptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.